MAIA Biotechnology
MAIA
Market cap $45.7M

1.58 USD

-0.02

1.25%

At close Mar 13, 4:00 PM EDT

After hours

1.50

-0.08

5.06%

1 day

-1.25%

5 days

-9.20%

1 month

-15.51%

3 months

-21.00%

6 months

-48.53%

Year to date

-24.40%

1 year

17.91%

5 years

-64.57%

10 years

-64.57%

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Employees: 13

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 7,372 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

12% more funds holding

Funds holding: 17 [Q3] → 19 (+2) [Q4]

0.85% less ownership

Funds ownership: 6.14% [Q3] → 5.29% (-0.85%) [Q4]

34% less capital invested

Capital invested by funds: $4.15M [Q3] → $2.75M (-$1.4M) [Q4]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MAIA.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about MAIA published over the past 30 days

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

CHICAGO--(BUSINESS WIRE)--MAIA to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced NSCLC Patients.

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer (NSCLC). Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy w.

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million.

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

MAIA Biotechnology Announces Private Placement of $2,715,000

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of $2,715,000.

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer.

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at Biotech Showcase 2025

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2025.

MAIA Biotechnology to Present at Biotech Showcase 2025

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings.

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas.

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

MAIA Biotechnology Announces Private Placement of Approximately $950,000

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of Approximately $950,000.

MAIA Biotechnology Announces Private Placement of Approximately $950,000

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer.

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

See News Rankings

Charts implemented using Lightweight Charts™